miR-449 can inhibit SIRT1-SREBP signaling by reducing the expression of SIRT1, SREBP1c, and its downstream genes FASN and HMGCR, thereby controlling adipogenesis and cholesterol production in hepatoma cells. Here, SIRT1 is linked to hepatocellular carcinoma.